V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20187472 | 20088192 | 1.56 | null | 03 | 2017-11-26 | 2017-11-28 | EOF | 02 | N | NIVOLUMAB | 101395921 |
| 20187474 | 20088193 | null | null | Palliative (P) | 2017-11-21 | 2017-12-05 | Irinotecan 14day | 02 | Y | RITUXIMAB | 100259446 |
| 20187592 | 20088195 | 1.73 | 82.1 | Adjuvant (A) | null | 2018-03-17 | ECarboX | 01 | N | FEC + DOCETAXEL | 101618172 |
| 20187761 | 20088196 | 1.5 | 92 | null | 2020-05-09 | 2020-05-09 | Rituximab | N | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 100752154 |
| 20187852 | 20088197 | 1.47 | 96 | Palliative (P) | 2018-12-15 | 2019-01-03 | LENALIDOMIDE | 02 | null | AZACITIDINE | 101723951 |
| 20188227 | 20088199 | 1.59 | 47.2 | Neo-adjuvant (N) | 2018-05-20 | 2018-05-30 | Doxorubicin + Olaratumab | null | N | SCOPE2 TRIAL | 101144719 |
| 20188476 | 20088201 | 1.57 | 60 | 03 | 2018-03-08 | 2018-03-22 | Cisplatin + Radiotherapy | 01 | N | PACLITAXEL | 100443520 |
| 20188507 | 20088202 | 0 | 0 | 03 | 2017-12-13 | 2017-12-29 | ACTICCA-1 Trial | 02 | N | CHLORAMBUCIL + RITUXIMAB | 100759450 |
| 20188872 | 20088205 | 1.68 | 70.25 | 03 | 2018-09-15 | 2018-10-07 | Gemcitabine + Paclitaxel | 02 | N | NEO-AEGIS TRIAL | 100424375 |
| 20188987 | 20088206 | 1.69 | 70.6 | Palliative (P) | 2020-04-09 | 2020-04-10 | GO2 TRIAL | 02 | N | BALLAD TRIAL | 101684297 |
| 20189036 | 20088207 | 1.73 | 70.2 | 03 | 2016-04-03 | 2016-04-10 | Doxorubicin 75mg/m2 | N | N | EPIRUBICIN + FLUOROURACIL + OXALIPLATIN | 101870437 |
| 20189120 | 20088208 | 1.69 | 72.9 | Palliative (P) | 2017-01-03 | 2017-01-10 | Carboplatin + Liposomal Doxorubicin | 01 | N | CHOP | 100307706 |
| 20189383 | 20088209 | 1.73 | 69.5 | null | 2020-11-28 | 2020-11-28 | Temozolomide + RT | 02 | N | PRIMUS 002 TRIAL | 100701518 |
| 20189525 | 20088210 | 1.51 | 64.6 | Palliative (P) | 2017-11-28 | 2017-12-02 | ECarboX | 02 | null | CHLORAMBUCIL + OBINUTUZUMAB | 100131084 |
| 20189803 | 20088211 | 1.81 | 84.4 | Palliative (P) | 2017-07-21 | 2017-07-21 | CYCLOPHOSPHAMIDE | 02 | N | CAP + RT | 100286221 |
| 20189860 | 20088212 | 1.78 | 111.7 | 03 | null | 2016-12-30 | Docetaxel 75mg/m2 (21 day) | 01 | Y | HYDROXYCARBAMIDE | 100219824 |
| 20189888 | 20088213 | 1.79 | 73.5 | Adjuvant (A) | 2017-10-08 | 2017-10-19 | IPILIMUMAB + NIVOLUMAB | N | N | AML18 TRIAL | 100851622 |
| 20189892 | 20088214 | 1.67 | 71.5 | 03 | 2017-05-26 | 2017-05-26 | Bortezomib + Cyclophos + Dex | 02 | N | CVD | 100827881 |
| 20189948 | 20088215 | 1.82 | 94.5 | 03 | 2018-11-30 | 2018-12-04 | PLATFORM Trial | 02 | N | BENDAMUSTINE + RITUXIMAB | 100494024 |
| 20190046 | 20088217 | 1.75 | 83 | 03 | 2016-06-04 | 2016-06-20 | ARISTOTLE TRIAL | 02 | N | CISPLATIN + DOCETAXEL + FLUOROURACIL | 101597597 |
| 20190050 | 20088218 | 1.63 | 95 | 03 | 2016-03-26 | 2016-04-19 | CARBOPLATIN + GEMCITABINE | 02 | Y | DOCETAXEL | 101356560 |
| 20190080 | 20088219 | 1.8 | 55 | Palliative (P) | 2020-02-27 | 2020-02-27 | IDELALISIB + RITUXIMAB | 01 | N | SCOPE2 TRIAL | 101597281 |
| 20190292 | 20088220 | 1.63 | 77.8 | null | 2018-05-24 | 2018-05-30 | CHOP R - 21 days | 02 | N | RADIUM 223 | 101266166 |
| 20190312 | 20088221 | 1.65 | 88 | Palliative (P) | 2018-07-31 | 2018-08-10 | CAP + RT | 02 | N | SCOPE2 TRIAL | 100306812 |
| 20190382 | 20088222 | 1.75 | 82 | Palliative (P) | 2016-10-10 | 2016-10-11 | GemCarbo Days 1+8 | 02 | N | ARISTOTLE TRIAL | 100410051 |
| 20190492 | 20088223 | 1.66 | 71.4 | Palliative (P) | null | 2017-02-08 | EOF | N | N | MITOMYCIN | 101472699 |
| 20190704 | 20088224 | 1.77 | 72.1 | 03 | 2018-04-06 | 2018-04-06 | NEO-AEGIS TRIAL | 02 | N | CISPLATIN + RT | 101768149 |
| 20190743 | 20088225 | 1.79 | 62.4 | Palliative (P) | 2019-12-24 | 2019-12-29 | Cisplatin + Fluorouracil + RT 5day | 02 | N | HYDROXYCARBAMIDE | 100370418 |
| 20190786 | 20088226 | 1.78 | 76 | 03 | 2019-01-10 | 2019-01-10 | SCOPE 1 TRIAL | 02 | N | BORTEZOMIB + DARATUMUMAB | 101626160 |
| 20190944 | 20088228 | 1.77 | 83.4 | null | 2019-11-30 | 2019-11-30 | CISPLATIN + FU + TRASTUZUMAB | 02 | N | NEO-AEGIS TRIAL | 100510713 |
| 20190951 | 20088229 | 1.63 | 69.6 | Palliative (P) | 2017-12-27 | 2018-02-21 | GO2 TRIAL | 02 | null | BORTEZOMIB + CYCLOPHOSPHAMIDE | 101577790 |
| 20191187 | 20088231 | 0 | 0 | Adjuvant (A) | 2017-07-23 | 2017-07-30 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | CARBOPLATIN + FLUOROURACIL | 100212489 |
| 20191217 | 20088232 | 1.76 | 61.5 | Palliative (P) | 2018-06-08 | 2018-06-21 | ARISTOTLE TRIAL | 02 | N | PHITT B OR C CISPLATIN | 101013822 |
| 20191235 | 20088233 | 0 | 0 | 03 | 2017-08-09 | 2017-09-25 | PLATO Trials | 99 | N | PLATO TRIAL | 101254802 |
| 20191296 | 20088234 | 1.82 | 56.6 | null | 2019-05-11 | 2019-05-19 | Rituximab | 2 | N | IBRUTINIB | 101505778 |
| 20191351 | 20088235 | 1.74 | 69 | 03 | 2019-02-09 | 2019-02-09 | Vinorelbine (oral) | 02 | N | FCR | 101345723 |
| 20191412 | 20088236 | 1.79 | 59.55 | 03 | null | 2019-04-05 | null | N | N | CAP + RT | 100082914 |
| 20191467 | 20088237 | 1.71 | 66.4 | null | 2015-09-27 | 2018-09-13 | Bendamustine+Rituximab (1st Course) | 02 | N | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100543125 |
| 20191484 | 20088238 | 1.46 | 108 | null | 2019-12-12 | 2019-12-12 | CARBOPLATIN + RT | N | N | CAPECITABINE + OXALIPLATIN + TRASTUZUMAB | 101612776 |
| 20191682 | 20088239 | 1.7 | 62.2 | Palliative (P) | 2019-02-27 | 2019-03-26 | RUXOLITINIB | 02 | N | PHITT B OR C CISPLATIN | 101419562 |
| 20191722 | 20088240 | 0 | 15 | null | 2019-05-19 | 2019-05-27 | Raltitrexed | 02 | N | CISPLATIN + FLUOROURACIL + RT | 100789396 |
| 20191793 | 20088241 | 1.79 | 47 | 03 | 2019-11-03 | 2019-11-17 | EOF | 02 | N | CAPECITABINE + STREPTOZOCIN | 100438358 |
| 20191818 | 20088242 | 1.67 | 88.7 | 03 | 2021-05-04 | 2021-05-06 | ECarboX | 02 | Y | CYCLOPHOSPHAMIDE | 101184986 |
| 20191857 | 20088243 | 1.69 | 74.5 | 03 | 2018-11-29 | 2018-12-01 | CARBOPLATIN + FLUOROURACIL | 02 | Y | HYDROXYCARBAMIDE | 101789831 |
| 20191880 | 20088244 | 1.73 | 60.8 | 03 | 2017-07-11 | 2017-07-19 | FOXFIRE TRIAL | 02 | N | IXAZOMIB + LENALIDOMIDE | 100512570 |
| 20191964 | 20088245 | 1.79 | 78 | 03 | 2018-02-23 | 2018-03-10 | ACTICCA-1 Trial | 02 | N | BENDAMUSTINE + RITUXIMAB | 100219672 |
| 20191973 | 20088246 | null | 77 | Palliative (P) | 2018-06-03 | 2018-06-17 | ECarboX | 01 | N | BORTEZOMIB | 101738740 |
| 20192011 | 20088247 | 0 | 79.6 | null | null | 2017-05-18 | BCG Intravesical | 02 | N | PANITUMUMAB | 101367377 |
| 20192236 | 20088248 | 1.76 | 56.35 | Palliative (P) | 2016-05-01 | 2016-05-07 | Carboplatin+Fluorouracil 4 or 5 day | 02 | N | CAPECITABINE + LOMUSTINE | 101713994 |
| 20192351 | 20088249 | 1.6 | 41.8 | Palliative (P) | 2017-09-21 | 2017-09-23 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | BLEOMYCIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + MITOXANTRONE + PROCARBAZINE + VINBLASTINE | 100796546 |